Short- and Long-Term Effects of Weight Loss on the Complement Component C3 After Laparoscopic Gastric Bypass in Obese Patients

Obesity Surgery

Volumn 26, Issue 11, 2016, Pages 2756-2763

  Gómez Abril, Segundo Á ^a   Morillas Ariño, Carlos ^a   Ponce Marco, Jose L ^b   Torres Sánchez, Teresa ^a   Delgado Gomis, Fernando ^a   Hernández Mijares, Antonio ^a,c   Rocha, Milagros ^a,c  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

C3c; Gastric bypass; Humans; Insulin resistance; Long term

Indexed keywords

ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; COMPLEMENT COMPONENT C3; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LACTATE DEHYDROGENASE; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; C3 PROTEIN, HUMAN;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; GASTRIC BYPASS SURGERY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LAPAROSCOPIC SURGERY; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; AGED; BLOOD; FOLLOW UP; LAPAROSCOPY; METABOLISM; MIDDLE AGED; MORBID OBESITY; PHYSIOLOGY; PROCEDURES; REHABILITATION; TIME FACTOR; YOUNG ADULT;

ADULT; AGED; BIOMARKERS; COMPLEMENT C3; FEMALE; FOLLOW-UP STUDIES; GASTRIC BYPASS; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; OBESITY, MORBID; TIME FACTORS; WEIGHT LOSS; YOUNG ADULT;

EID: 84965076044     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-016-2195-z     Document Type: Article

References (44)

1. Ricklin D, Hajishengallis G, Yang K, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–97.
2. Haskard DO, Boyle JJ, Mason JC. The role of complement in atherosclerosis. Curr Opin Lipidol. 2008;19:478–82.
3. Onat A, Can G, Rezvani R, et al. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta. 2011;412:1171–9.
4. Hertle E, van Greevenbroek MM, Stehouwer CD. Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia. 2012;55:881–4.
5. Wlazlo N, van Greevenbroek MM, Ferreira I, et al. Complement factor 3 is associated with insulin resistance and with incident type 2 diabetes over a 7-year follow-up period: the CODAM Study. Diabetes Care. 2014;37:1900–9.
6. Unsworth DJ. Complement deficiency and disease. J Clin Pathol. 2008;61:1013–7.
7. Gabrielsson BG, Johansson JM, Lönn M, et al. High expression of complement components in omental adipose tissue in obese men. Obes Res. 2003;11:699–708.
8. Hernández-Mijares A, Jarabo-Bueno MM, López-Ruiz A, et al. Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors. Int J Obes. 2007;31:927–32.
9. Peake PW, Kriketos AD, Campbell LV, et al. Response of the alternative complement pathway to an oral fat load in first-degree relatives of subjects with type II diabetes. Int J Obes. 2005;29:429–35.
10. Hanusch-Enserer U, Cauza E, Spak M, et al. Acute-phase response and immunological markers in morbid obese patients and patients following adjustable gastric banding. Int J Obes Relat Metab Disord. 2003;27:355–61.
11. Sakçak I, Avşar MF, Hamamci EO, et al. Comparison of early and late changes in immunoglobulins and acute phase reactants after laparoscopic adjustable gastric banding in patients with morbid obesity. Obes Surg. 2010;20:610–5.
12. Nestvold TK, Nielsen EW, Ludviksen JK, et al. Lifestyle changes followed by bariatric surgery lower inflammatory markers and the cardiovascular risk factors C3 and C4. Metab Syndr Relat Disord. 2015;13:29–35.
13. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–52.
14. Luján JA, Hernández Q, Frutos MD, et al. Laparoscopic gastric bypass in the treatment of morbid obesity. Preliminary results of a new technique. Surg Endosc. 2002;16:1658–62.
15. Puzziferri N, Roshek 3rd TB, Mayo HG, et al. Long-term follow-up after bariatric surgery: a systematic review. JAMA. 2014;312:934–42.
16. Magro DO, Geloneze B, Delfini R, et al. Long-term weight regain after gastric bypass: a 5-year prospective study. Obes Surg. 2008;18:648–51.
17. Meguid MM, Glade MJ, Middleton FA. Weight regain after Roux-en-Y: a significant 20% complication related to PYY. Nutrition. 2008;24:832–42.
18. Faria SL, Kelly E, Faria OP. Energy expenditure and weight regain in patients submitted to Roux-en-Y gastric bypass. Obes Surg. 2009;19:856–9.
19. Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.
20. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.
21. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B–12B.
22. Després JP, Lemieux I, Dagenais GR, et al. HDL-cholesterol as a marker of coronary heart disease risk: the Québec Cardiovascular Study. Atherosclerosis. 2000;153:263–72.
23. Ashen MD, Blumenthal RS. Clinical practice. Low HDL cholesterol levels. N Engl J Med. 2005;353:1252–60.
24. Rashid S, Barrett PH, Uffelman KD, et al. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler Thromb Vasc Biol. 2002;22:483–7.
25. Côté M, Mauriège P, Bergeron J, et al. Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab. 2005;90:1434–9.
26. Broedl UC, Jin W, Rader DJ. Endothelial lipase: a modulator of lipoprotein metabolism upregulated by inflammation. Trends Cardiosvasc Med. 2004;14:202–6.
27. Nilsson B, Hamad OA, Ahlström H, et al. C3 and C4 are strongly related to adipose tissue variables and cardiovascular risk factors. Eur J Clin Invest. 2014;44:587–96.
28. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–5.
29. Hernández-Mijares A, Bañuls C, Bellod L, et al. Effect of weight loss on C3 and C4 components of complement in obese patients. Eur J Clin Invest. 2012;42:503–9.
30. Anty R, Bekri S, Luciani N, et al. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, type 2 diabetes, and NASH. Am J Gastroenterol. 2006;101:1824–33.
31. Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care. 1999;22:1971–7.
32. Vázquez LA, Pazos F, Berrazueta JR, et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab. 2005;90:316–22.
33. Anty R, Dahman M, Iannelli A, et al. Bariatric surgery can correct iron depletion in morbidly obese women: a link with chronic inflammation. Obes Surg. 2008;18:709–14.
34. Vilarrasa N, Vendrell J, Sánchez-Santos R, et al. Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-alpha receptors, C-reactive protein and adiponectin in morbidly obese patients. Clin Endocrinol (Oxf). 2007;67:679–86.
35. Rezvani R, Smith J, Lapointe M, et al. Complement receptors C5aR and C5L2 are associated with metabolic profile, sex hormones, and liver enzymes in obese women pre- and postbariatric surgery. J Obes. 2014;2014:383102.
36. van Greevenbroek MM, Jacobs M, van der Kallen CJ, et al. The cross-sectional association between insulin resistance and circulating complement C3 is partly explained by plasma alanine aminotransferase, independent of central obesity and general inflammation (the CODAM Study). Eur J Clin Invest. 2011;41:372–9.
37. Muscari A, Antonelli S, Bianchi G, et al. Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: comparison study in an elderly population. Diabetes Care. 2007;30:2362–8.
38. Yesilova Z, Ozata M, Oktenli C, et al. Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance. Am J Gastroenterol. 2005;100:842–9.
39. Fiorentino TV, Hribal ML, Andreozzi F, et al. Plasma complement C3 levels are associated with insulin secretion independently of adiposity measures in non-diabetic individuals. Nutr Metab Cardiovasc Dis. 2015;25:510–7.
40. Barbu A, Hamad OA, Lind L, et al. The role of complement factor C3 in lipid metabolism. Mol Immunol. 2015;67:101–7.
41. Maslowska M, Wang HW, Cianflone K. Novel roles for acylation stimulating protein/C3adesArg: a review of recent in vitro and in vivo evidence. Vitam Horm. 2005;70:309–32.
42. van Greevenbroek MM, Jacobs M, van der Kallen CJ, et al. Human plasma complement C3 is independently associated with coronary heart disease, but only in heavy smokers (the CODAM Study). Int J Cardiol. 2012;154:158–62.
43. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117:746–56.
44. Distelmaier K, Adlbrecht C, Jakowitsch J, et al. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost. 2009;102:564–72.